Celltrion Pharm, Inc. (KOSDAQ:068760)

South Korea · Delayed Price · Currency is KRW

45,900

+900 (2.00%)

Aug 11, 2026, 12:50 PM KST

-11.50% (1Y)

Market Cap	1.99T -13.5%
Revenue (ttm)	274.73B +53.2%
Net Income	26.03B +146.8%
EPS	583.36 +146.0%
Shares Out	44.21M
PE Ratio	77.14
Forward PE	n/a
Dividend	200.00 (0.45%)
Ex-Dividend Date	Dec 29, 2025

Volume	82,577
Open	44,750
Previous Close	45,000
Day's Range	44,550 - 47,000
52-Week Range	37,000 - 78,300
Beta	0.92
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About Celltrion Pharm

Celltrion Pharm, Inc., a pharmaceutical company, develops and sells biosimilars and over-the-counter drugs in South Korea. The company offers hepatotonic, anti-inflammatory, antihistamine, respiratory apparatus, circulary system, digestive and stomachic, hormone/metabolic disease, antibiotic/antimycotic, nutrientia and tonic, immunology, oncology, and other drugs. It serves university hospitals and general pharmacies. Celltrion Pharm Inc. was founded in 1976 and is based in Cheongju-si, South Korea. Celltrion Pharm, Inc. (KOSDAQ:A068760) operat... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 1976

Employees 328

Stock Exchange KOSDAQ

Ticker Symbol 068760

Full Company Profile

Financial Performance

In 2020, Celltrion Pharm's revenue was 233.57 billion, an increase of 34.61% compared to the previous year's 173.51 billion. Earnings were 20.94 billion, an increase of 143.42%.

Financial Statements